Charles Schwab Investment Management Inc. Has $1.09 Billion Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Charles Schwab Investment Management Inc. raised its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,227,467 shares of the medical equipment provider’s stock after purchasing an additional 28,703 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.63% of Intuitive Surgical worth $1,094,288,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. Banco Santander S.A. lifted its holdings in shares of Intuitive Surgical by 1.3% during the 3rd quarter. Banco Santander S.A. now owns 54,755 shares of the medical equipment provider’s stock worth $26,899,000 after acquiring an additional 703 shares during the period. L & S Advisors Inc boosted its stake in Intuitive Surgical by 48.9% in the third quarter. L & S Advisors Inc now owns 22,427 shares of the medical equipment provider’s stock worth $11,018,000 after purchasing an additional 7,362 shares in the last quarter. DE Burlo Group Inc. increased its stake in shares of Intuitive Surgical by 140.6% in the third quarter. DE Burlo Group Inc. now owns 26,950 shares of the medical equipment provider’s stock valued at $13,240,000 after buying an additional 15,750 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new position in shares of Intuitive Surgical in the third quarter valued at about $558,807,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in Intuitive Surgical during the 3rd quarter worth about $281,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Trading Down 0.0 %

Shares of NASDAQ ISRG opened at $541.72 on Thursday. The company has a fifty day moving average price of $502.44 and a 200 day moving average price of $461.26. Intuitive Surgical, Inc. has a 1-year low of $304.50 and a 1-year high of $546.32. The firm has a market cap of $192.95 billion, a PE ratio of 87.11, a PEG ratio of 5.30 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Equities research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Insider Activity at Intuitive Surgical

In related news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 93.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jamie Samath sold 269 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now directly owns 8,757 shares of the company’s stock, valued at $4,727,816.73. This represents a 2.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 91,178 shares of company stock valued at $45,897,071. Corporate insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ISRG shares. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Robert W. Baird increased their price objective on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler reissued an “overweight” rating and set a $538.00 price objective (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. Finally, Mizuho upped their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average price target of $524.61.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.